ELTX vs. CYRX, RCKT, VSTM, ABEO, URGN, HRTX, ATXS, TRDA, NGNE, and XOMA
Should you be buying Elicio Therapeutics stock or one of its competitors? The main competitors of Elicio Therapeutics include Cryoport (CYRX), Rocket Pharmaceuticals (RCKT), Verastem (VSTM), Abeona Therapeutics (ABEO), UroGen Pharma (URGN), Heron Therapeutics (HRTX), Astria Therapeutics (ATXS), Entrada Therapeutics (TRDA), Neurogene (NGNE), and XOMA (XOMA).
Elicio Therapeutics vs. Its Competitors
CryoPort (NASDAQ:CYRX) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap transportation companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.
CryoPort presently has a consensus price target of $11.00, indicating a potential upside of 72.68%. Elicio Therapeutics has a consensus price target of $10.00, indicating a potential upside of 24.22%. Given CryoPort's higher possible upside, equities research analysts plainly believe CryoPort is more favorable than Elicio Therapeutics.
CryoPort received 245 more outperform votes than Elicio Therapeutics when rated by MarketBeat users. However, 77.78% of users gave Elicio Therapeutics an outperform vote while only 65.80% of users gave CryoPort an outperform vote.
Elicio Therapeutics has a net margin of 0.00% compared to CryoPort's net margin of -50.15%. Elicio Therapeutics' return on equity of 0.00% beat CryoPort's return on equity.
92.9% of CryoPort shares are owned by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are owned by institutional investors. 10.1% of CryoPort shares are owned by insiders. Comparatively, 28.7% of Elicio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, CryoPort had 8 more articles in the media than Elicio Therapeutics. MarketBeat recorded 9 mentions for CryoPort and 1 mentions for Elicio Therapeutics. CryoPort's average media sentiment score of 0.27 beat Elicio Therapeutics' score of 0.00 indicating that CryoPort is being referred to more favorably in the media.
CryoPort has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500. Comparatively, Elicio Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.
Elicio Therapeutics has lower revenue, but higher earnings than CryoPort. CryoPort is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
CryoPort beats Elicio Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Elicio Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ELTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elicio Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ELTX) was last updated on 6/23/2025 by MarketBeat.com Staff
Buy ELTX Stock Free ELTX Stock Alerts